SI3415515T1 - Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata - Google Patents

Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata

Info

Publication number
SI3415515T1
SI3415515T1 SI201031982T SI201031982T SI3415515T1 SI 3415515 T1 SI3415515 T1 SI 3415515T1 SI 201031982 T SI201031982 T SI 201031982T SI 201031982 T SI201031982 T SI 201031982T SI 3415515 T1 SI3415515 T1 SI 3415515T1
Authority
SI
Slovenia
Prior art keywords
methylcarbamate
fluorobenzyl
pyrazolo
pyrimidin
diamino
Prior art date
Application number
SI201031982T
Other languages
English (en)
Inventor
Franz-Josef Mais
Joachim Rehse
Winfried Joentgen
Konrad Siegel
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43536603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3415515(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of SI3415515T1 publication Critical patent/SI3415515T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C325/00—Thioaldehydes; Thioketones; Thioquinones; Oxides thereof
    • C07C325/02—Thioketones; Oxides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201031982T 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata SI3415515T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09177371 2009-11-27
EP18178602.1A EP3415515B1 (de) 2009-11-27 2010-11-22 Verfahren zur herstellung von methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat

Publications (1)

Publication Number Publication Date
SI3415515T1 true SI3415515T1 (sl) 2020-03-31

Family

ID=43536603

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201030773T SI2504334T1 (sl) 2009-11-27 2010-11-22 Postopek čiščenja (4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo-(3,4-b)piridin-3-il)piri midin-5-il)metilkarbamata
SI201031061T SI2604608T1 (sl) 2009-11-27 2010-11-22 Postopek izdelave metil-(4,6-diamino-2(1-(2-fluorobenzil)-1H-pirazolo (3,4-b)piridin-3-il)-pirimidin-5-il)metil karbamata in njegovo čiščenje za uporabo kot farmacevtsko sredstvo
SI201031982T SI3415515T1 (sl) 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata
SI201031762T SI2733142T1 (sl) 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3il) pirimidin-5-il)metilkarbamata za uporabo kot farmacevtska učinkovina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI201030773T SI2504334T1 (sl) 2009-11-27 2010-11-22 Postopek čiščenja (4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo-(3,4-b)piridin-3-il)piri midin-5-il)metilkarbamata
SI201031061T SI2604608T1 (sl) 2009-11-27 2010-11-22 Postopek izdelave metil-(4,6-diamino-2(1-(2-fluorobenzil)-1H-pirazolo (3,4-b)piridin-3-il)-pirimidin-5-il)metil karbamata in njegovo čiščenje za uporabo kot farmacevtsko sredstvo

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201031762T SI2733142T1 (sl) 2009-11-27 2010-11-22 Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3il) pirimidin-5-il)metilkarbamata za uporabo kot farmacevtska učinkovina

Country Status (43)

Country Link
US (5) US8492544B2 (sl)
EP (5) EP2733142B1 (sl)
JP (4) JP5859451B2 (sl)
KR (2) KR101766931B1 (sl)
CN (2) CN102791707B (sl)
AR (1) AR079134A1 (sl)
AU (3) AU2010323227B2 (sl)
BR (3) BR112012012617B8 (sl)
CA (2) CA2781799C (sl)
CL (1) CL2012001329A1 (sl)
CO (1) CO6551708A2 (sl)
CR (1) CR20120280A (sl)
CU (1) CU24084B1 (sl)
CY (1) CY1115861T1 (sl)
DK (4) DK3415515T3 (sl)
DO (2) DOP2012000144A (sl)
EA (3) EA036422B1 (sl)
EC (2) ECSP12011921A (sl)
ES (4) ES2524826T3 (sl)
GT (1) GT201200158A (sl)
HK (2) HK1178899A1 (sl)
HR (4) HRP20141073T1 (sl)
HU (2) HUE040328T2 (sl)
IL (4) IL219683A (sl)
JO (3) JO3107B1 (sl)
LT (2) LT3415515T (sl)
MA (1) MA33783B1 (sl)
MX (1) MX2012005938A (sl)
MY (2) MY180184A (sl)
NZ (3) NZ600199A (sl)
PE (2) PE20180203A1 (sl)
PL (4) PL2504334T3 (sl)
PT (4) PT2504334E (sl)
RS (4) RS54433B1 (sl)
SI (4) SI2504334T1 (sl)
SM (1) SMT201400164B (sl)
TN (1) TN2012000257A1 (sl)
TR (1) TR201816146T4 (sl)
TW (1) TWI496781B (sl)
UA (1) UA110779C2 (sl)
UY (1) UY33048A (sl)
WO (1) WO2011064171A2 (sl)
ZA (1) ZA201204610B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171255A1 (es) 2009-11-27 2017-08-28 Genzyme Corp Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
BR112012012617B8 (pt) * 2009-11-27 2021-05-25 Adverio Pharma Gmbh processo para a produção de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EA030018B1 (ru) 2011-11-25 2018-06-29 Адверио Фарма Гмбх Способ получения замещенного 5-фтор-1h-пиразолопиридина
JP6386478B2 (ja) 2013-02-21 2018-09-05 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１ｈ−ピラゾロ［３，４−ｂ］ピリジノ−３−イル］ピリミジノ−５−イル｝メチルカルバメートの形態
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
AU2015316796A1 (en) 2014-09-19 2017-03-30 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as Bub1 inhibitors
WO2016113415A1 (en) 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
CN105367568B (zh) * 2015-11-18 2019-08-20 浙江京新药业股份有限公司 一种制备利奥西呱的方法
CN105294686B (zh) * 2015-11-30 2017-03-22 郑州大明药物科技有限公司 一种利奥西呱的制备方法
CA3006764A1 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
US10414766B2 (en) * 2015-12-15 2019-09-17 Alembic Pharmaceuticals Limited Polymorph of Riociguat and its process for the preparation
CN108069960A (zh) * 2016-11-15 2018-05-25 江苏豪森药业集团有限公司 利奥西呱中间体的制备方法
WO2018096550A1 (en) * 2016-11-28 2018-05-31 Msn Laboratories Private Limited, R&D Center Process for the preparation of methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate and its polymorphs thereof
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018130226A1 (zh) * 2017-01-16 2018-07-19 苏州科睿思制药有限公司 利奥西呱的新晶型及其制备方法和用途
BR112021000358A2 (pt) 2018-07-11 2021-04-06 Cyclerion Therapeutics, Inc. Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais
EP4099987A1 (en) * 2020-02-03 2022-12-14 Adverio Pharma GmbH Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
CN111689961A (zh) * 2020-06-01 2020-09-22 江苏华阳制药有限公司 一种利奧西呱的新晶型及其制备方法
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
CN112316932B (zh) * 2020-11-13 2022-03-01 中国石油大学(北京) 一种粗对苯二甲酸加氢精制催化剂及其制备方法和应用
CN112316968B (zh) * 2020-11-13 2022-03-01 中国石油大学(北京) 一种粗对苯二甲酸加氢精制催化剂及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950350A (en) * 1974-12-27 1976-04-13 Pfizer Inc. Penam-dimethylsulfoxide complex
US4970210A (en) * 1987-07-17 1990-11-13 Abbott Laboratories Triazinone lipoxygenase compounds
ATE120169T1 (de) * 1989-07-18 1995-04-15 Atochem Elf Sa Verfahren zur reinigung von 1,1-bis(4- chlorphenyl)-2,2,2-trichlorethanol.
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
JP4351298B2 (ja) * 1996-10-14 2009-10-28 バイエル・アクチエンゲゼルシヤフト 新規へテロシクリルメチル置換ピラゾール誘導体
CN100430396C (zh) * 1997-11-12 2008-11-05 拜耳医药保健股份公司 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
EP1339716B1 (de) * 2000-11-22 2004-11-03 Bayer HealthCare AG lactam-substituierte pyrazolopyridinderivate
DE10057751A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057754A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE10122894A1 (de) * 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) * 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
US6738631B1 (en) 2002-05-06 2004-05-18 Nokia, Inc. Vision-guided model-based point-and-click interface for a wireless handheld device
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP4299573B2 (ja) * 2003-04-25 2009-07-22 東洋シヤッター株式会社 エレベータの扉装置
DE10222550A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
KR200342343Y1 (ko) 2003-11-17 2004-02-18 김강철 탄성체 유희용구
KR20070008674A (ko) * 2004-04-01 2007-01-17 아스테라스 세이야쿠 가부시키가이샤 피라진 유도체, 및 아데노신 길항제로서의 이의 약학적용도
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102009004245A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
BR112012012617B8 (pt) * 2009-11-27 2021-05-25 Adverio Pharma Gmbh processo para a produção de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato
UY33041A (es) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
UY33040A (es) 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
JP5976788B2 (ja) 2011-05-06 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用
ES2648810T3 (es) 2011-07-06 2018-01-08 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de la guanilato ciclasa soluble
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
EP2822951B1 (de) 2012-03-06 2017-07-26 Bayer Intellectual Property GmbH Substituierte azabicyclen und ihre verwendung
BR112015020298A2 (pt) 2013-03-01 2017-07-18 Bayer Pharma AG pirimidinas de anel fundido substituídas com trifluormetil e uso das mesmas

Also Published As

Publication number Publication date
ES2553035T3 (es) 2015-12-03
NZ625983A (en) 2016-02-26
TW201200514A (en) 2012-01-01
IL240878B (en) 2018-08-30
JO3651B1 (ar) 2020-08-27
DK3415515T3 (da) 2020-03-16
RS53585B1 (en) 2015-02-27
DK2604608T3 (en) 2015-12-07
US10030014B2 (en) 2018-07-24
IL251603A0 (en) 2017-06-29
EA201270636A1 (ru) 2013-01-30
CA2936852C (en) 2019-10-29
JP6514398B2 (ja) 2019-05-15
US8853398B2 (en) 2014-10-07
WO2011064171A2 (de) 2011-06-03
US10570130B2 (en) 2020-02-25
EP2504334B1 (de) 2014-10-01
EP2733142A2 (de) 2014-05-21
KR101861981B1 (ko) 2018-05-28
AR079134A1 (es) 2011-12-28
SMT201400164B (it) 2015-01-15
DOP2012000144A (es) 2012-11-15
NZ600199A (en) 2014-06-27
AU2015243005B2 (en) 2017-06-01
US20140288303A1 (en) 2014-09-25
WO2011064171A3 (de) 2011-08-11
MX2012005938A (es) 2012-09-12
BR112012012617B1 (pt) 2021-04-27
AU2017203023B2 (en) 2018-11-08
CN104059064B (zh) 2019-06-04
IL251601B (en) 2019-05-30
HUE040328T2 (hu) 2019-03-28
GT201200158A (es) 2014-04-03
CU20120082A7 (es) 2012-10-15
CA2781799A1 (en) 2011-06-03
SI2504334T1 (sl) 2014-11-28
BR122019002289B1 (pt) 2021-09-28
CN104059064A (zh) 2014-09-24
JP5859451B2 (ja) 2016-02-10
JP6371871B2 (ja) 2018-08-08
UY33048A (es) 2011-06-30
MY180184A (en) 2020-11-24
EP2504334A2 (de) 2012-10-03
EP3699180A1 (de) 2020-08-26
BR122019002291B8 (pt) 2021-05-25
ES2693746T3 (es) 2018-12-13
RS57790B1 (sr) 2018-12-31
US10351562B2 (en) 2019-07-16
JO3650B1 (ar) 2020-08-27
HK1178899A1 (en) 2013-09-19
PE20180203A1 (es) 2018-01-31
TWI496781B (zh) 2015-08-21
EA022813B1 (ru) 2016-03-31
US20110130410A1 (en) 2011-06-02
JP2017081971A (ja) 2017-05-18
HRP20141073T1 (hr) 2015-01-02
DK2733142T3 (en) 2018-11-19
EP3415515A1 (de) 2018-12-19
AU2010323227B2 (en) 2015-11-19
AU2015243005A1 (en) 2015-11-05
US20180282329A1 (en) 2018-10-04
AU2010323227A1 (en) 2012-06-14
EA036422B1 (ru) 2020-11-09
UA110779C2 (uk) 2016-02-25
CN102791707A (zh) 2012-11-21
EP2733142B1 (de) 2018-08-01
DK2504334T3 (en) 2014-12-08
BR112012012617B8 (pt) 2021-05-25
BR122019002291B1 (pt) 2021-04-27
EP3415515B1 (de) 2019-12-25
JP6133931B2 (ja) 2017-05-24
IL219683A0 (en) 2012-07-31
IL219683A (en) 2015-09-24
PL2504334T3 (pl) 2015-02-27
CO6551708A2 (es) 2012-10-31
IL251601A0 (en) 2017-06-29
ZA201204610B (en) 2014-09-25
KR101766931B1 (ko) 2017-08-09
EP2604608A3 (de) 2013-08-07
CU24084B1 (es) 2015-03-30
CR20120280A (es) 2013-04-22
HRP20151243T1 (hr) 2015-12-18
KR20120123258A (ko) 2012-11-08
SI2604608T1 (sl) 2015-12-31
LT3415515T (lt) 2020-03-10
TR201816146T4 (tr) 2018-11-21
JP2013512212A (ja) 2013-04-11
SI2733142T1 (sl) 2018-10-30
EA201891964A1 (ru) 2019-01-31
HUE026778T2 (en) 2016-08-29
PL2733142T3 (pl) 2019-03-29
EP2733142A3 (de) 2014-10-15
CY1115861T1 (el) 2017-01-25
LT2733142T (lt) 2018-10-10
PT2604608E (pt) 2015-11-26
PT2733142T (pt) 2018-11-15
HRP20200397T1 (hr) 2020-06-12
JO3107B1 (ar) 2017-09-20
PT2504334E (pt) 2014-12-03
HRP20181785T1 (hr) 2018-12-28
AU2017203023A1 (en) 2017-05-25
US20130310563A1 (en) 2013-11-21
CA2781799C (en) 2017-05-02
PL2604608T3 (pl) 2016-02-29
RS54433B1 (en) 2016-04-28
EA201590948A1 (ru) 2016-01-29
KR20170093992A (ko) 2017-08-16
PL3415515T3 (pl) 2020-06-01
MY173711A (en) 2020-02-17
NZ715101A (en) 2017-07-28
TN2012000257A1 (en) 2013-12-12
EP2604608A2 (de) 2013-06-19
EP2604608B1 (de) 2015-10-07
ECSP18018453A (es) 2018-04-30
RS59908B1 (sr) 2020-03-31
US8492544B2 (en) 2013-07-23
PE20121742A1 (es) 2012-12-13
PT3415515T (pt) 2020-03-10
BR112012012617A2 (pt) 2015-09-08
MA33783B1 (fr) 2012-11-01
JP2015205887A (ja) 2015-11-19
CA2936852A1 (en) 2011-06-03
JP2018150383A (ja) 2018-09-27
US20190284186A1 (en) 2019-09-19
IL251603B (en) 2019-05-30
ECSP12011921A (es) 2012-07-31
ES2775902T3 (es) 2020-07-28
DOP2020000062A (es) 2020-09-30
EA031632B1 (ru) 2019-01-31
CN102791707B (zh) 2014-10-29
IL240878A0 (en) 2015-10-29
CL2012001329A1 (es) 2013-07-05
ES2524826T3 (es) 2014-12-12
HK1202292A1 (en) 2015-09-25

Similar Documents

Publication Publication Date Title
SI3415515T1 (sl) Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata
SI2419428T1 (sl) Imidazo (1,2-a) piridin derivati kot FGFR kinaza inhibitorji za uporabo v terapiji
IL184717A0 (en) Imidazo (1,2-a)pyridine compounds as vegf-r2 inhibitors
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
SI3178819T1 (sl) 5-Phenyl-(1,2,4)triazolo(1,5-A)pyridin-2-yl karboksamidi kot inhibitorji JAK
ZA201204028B (en) Imidazo[1.2-a]pyridine compounds, sysnthesis thereof, and methods of using same
SI2609082T1 (sl) Imidazo(4,5-c)kinolini kot inhibitorji dna-pk
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
IL206905A0 (en) 4-(pyrrolo[2,3-c]pyridine-3-yl)pyrimidin-2-
IL219826A0 (en) Novel polymorphic forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
IL219861A0 (en) Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound
IL233066B (en) Method for preparing 1-(2-fluorobenzyl)-h1-pyrazolo[b-3,4]pyridine-3-formamidine hydrochloride
SG10201408059QA (en) 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
IL219712A0 (en) Novel solvates of methyl {4, 6 -diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b] pyridin - 3 - yl] pyrimidin - 5 -yl} carbamate
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
EP2565194A4 (en) Imidazo [1,2-A] pyridine
GB2464854B (en) Process for the preparation of risperidone